The difficulties in treating bladder cancer with immunotherapy

Although it is typically well-tolerated, checkpoint blockade does not seem to significantly benefit bladder cancer patients, says Jonathan Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY. Dr Rosenberg discusses the response rates of bladder cancer patients receiving PD-1 or PD-L1-based therapies, and explains the phenomenon of pseudoprogression in urothelial carcinoma, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

• categoría